A scalable CAR-T cell manufacturing workflow producing 100+ doses per batch

Webinar | A scalable CAR-T cell manufacturing workflow producing 100+ doses per batch

A scalable CAR-T cell manufacturing workflow producing 100+ doses per batch

On-Demand Webinar

This webinar presents data from a collaborative study between University College London, Sartorius, and Repligen, demonstrating a scalable allogeneic anti-CD19 CAR-T manufacturing workflow. Attendees will gain practical, evidence-based strategies for scaling up CAR-T bioprocesses in single-use stirred-tank bioreactors from early development to clinical manufacturing, while maintaining product quality and reducing process risk.

The session includes a detailed case study covering cell growth, metabolism, phenotype, and in vitro cytotoxicity data, demonstrating 125-fold cell expansion and production of 100+ CAR-T doses per batch with high viability and a central memory-enriched, low-exhaustion phenotype.

What You Will Learn:

Review data from a 250 mL to 2 L scale-up of an anti-CD19 CAR-T workflow in single-use stirred-tank bioreactors using a serum-free medium
Understand how alternating tangential flow (ATF) perfusion can maximize CAR-T cell yields and support robust, high-density cultures
Evaluate a validated 250 mL scale-down model to streamline process development and reduce risk ahead of clinical-scale manufacturing
Gain practical guidance on implementing bio-capacitance for real-time, online monitoring of CAR-T cell concentrations
Learn how automated harvesting and buffer exchange influence critical quality attributes

Clear form data

Please Complete the Form

First Name *

Last Name *

Email *

Phone Number *

Company *

Job Title *

Address *

Country *

Postal Code *

I would like to sign up for newsletters from Sartorius (Sartorius AG and its affiliated companies) based of my personal interests.
I can revoke my consent at any time with effect for the future by sending an e-mail to unsubscribe@sartorius.com or by clicking on the "unsubscribe" link in e-mails I have received.

* These fields are required Information on the use of your data can be found in our privacy policy

Complete Form to Register

Rukmini Ladi

Segment Technology Manager, Cell Therapy at Sartorius

Rukmini is a Bioprocess Development Engineer with several years of experience in immune and stem cell therapies. As a Segment Technology Manager at Sartorius, she supports cell therapy developers with process design and optimization, focusing on scalable and efficient manufacturing. She also leads collaborations with industry and academic partners to advance cell therapy solutions.

Pierre Springuel, PhD

Marketeer, Cell and Gene Therapy at Sartorius

Pierre holds a PhD in Biochemical Engineering from the University College London, with research focused on CAR‑T process intensification and scale‑up in stirred‑tank bioreactors.